Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 160

  • Showing results for ben ari z. Search instead for Benari Z (1 item)
1.

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R.

Lancet Gastroenterol Hepatol. 2017 Aug 9. pii: S2468-1253(17)30159-0. doi: 10.1016/S2468-1253(17)30159-0. [Epub ahead of print]

PMID:
28802816
2.

Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.

Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L; C-CREST Part C and C-SURGE Investigators.

Hepatology. 2017 Jul 7. doi: 10.1002/hep.29358. [Epub ahead of print]

PMID:
28688129
3.

The Role of Liver Segment-to-Spleen Volume Ratio in the Staging of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection.

Lotan E, Raskin SP, Amitai MM, Kleinbaum Y, Veitsman E, Weiss P, Cohen-Ezra O, Berdichevski T, Ben-Ari Z.

Isr Med Assoc J. 2017 Apr;19(4):251-256.

4.

Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation.

Kagan P, Sultan M, Tachlytski I, Safran M, Ben-Ari Z.

PLoS One. 2017 May 4;12(5):e0176173. doi: 10.1371/journal.pone.0176173. eCollection 2017.

5.

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.

Polaris Observatory HCV Collaborators.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16.

PMID:
28404132
6.

Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.

Hézode C, Colombo M, Bourlière M, Spengler U, Ben-Ari Z, Strasser SI, Lee WM, Morgan L, Qiu J, Hwang P, Robertson M, Nguyen BY, Barr E, Wahl J, Haber B, Chase R, Talwani R, Marco VD; C-EDGE IBLD Study Investigators.

Hepatology. 2017 Sep;66(3):736-745. doi: 10.1002/hep.29139. Epub 2017 Jul 20.

PMID:
28256747
7.

HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.

Gozlan Y, Ben-Ari Z, Moscona R, Shirazi R, Rakovsky A, Kabat A, Veizman E, Berdichevski T, Weiss P, Cohen-Ezra O, Lurie Y, Gafanovich I, Braun M, Cohen-Naftaly M, Shlomai A, Shibolet O, Zigmond E, Zuckerman E, Carmiel-Haggai M, Nimer A, Hazzan R, Maor Y, Kitay-Cohen Y, Shemer-Avni Y, Kra-Oz Z, Schreiber L, Peleg O, Sierra S, Harrigan PR, Mendelson E, Mor O.

Antivir Ther. 2017 Jan 9. doi: 10.3851/IMP3123. [Epub ahead of print]

PMID:
28067632
8.

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.

Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, Kuo A, Lok AS, Shiffman ML, Ben Ari Z, Akushevich L, Vainorius M, Sulkowski MS, Fried MW, Nelson DR; HCV-TARGET Study Group.

Gastroenterology. 2016 Dec;151(6):1131-1140.e5. doi: 10.1053/j.gastro.2016.08.004. Epub 2016 Aug 24.

PMID:
27565882
9.

Positive antimitochondrial antibody but normal serum alkaline phosphatase levels: Could it be primary biliary cholangitis?

Berdichevski T, Cohen-Ezra O, Pappo O, Ben-Ari Z.

Hepatol Res. 2017 Jul;47(8):742-746. doi: 10.1111/hepr.12809. Epub 2016 Oct 4.

PMID:
27572231
10.

ADAR1 deletion induces NFκB and interferon signaling dependent liver inflammation and fibrosis.

Ben-Shoshan SO, Kagan P, Sultan M, Barabash Z, Dor C, Jacob-Hirsch J, Harmelin A, Pappo O, Marcu-Malina V, Ben-Ari Z, Amariglio N, Rechavi G, Goldstein I, Safran M.

RNA Biol. 2017 May 4;14(5):587-602. doi: 10.1080/15476286.2016.1203501. Epub 2016 Jun 30.

11.

Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.

Gane E, Ben Ari Z, Mollison L, Zuckerman E, Bruck R, Baruch Y, Howe AY, Wahl J, Bhanja S, Hwang P, Zhao Y, Robertson MN.

J Viral Hepat. 2016 Oct;23(10):789-97. doi: 10.1111/jvh.12552. Epub 2016 Jun 12.

PMID:
27291249
12.

Hepatitis E Virus Genotype 3 in Sewage and Genotype 1 in Acute Hepatitis Cases, Israel.

Ram D, Manor Y, Gozlan Y, Schwartz E, Ben-Ari Z, Mendelson E, Mor O.

Am J Trop Med Hyg. 2016 Jul 6;95(1):216-20. doi: 10.4269/ajtmh.15-0925. Epub 2016 May 31.

13.

[RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].

Gozlan Y, Mendelson E, Ben-Ari Z, Mor O.

Harefuah. 2015 Nov;154(11):684-7, 743. Hebrew.

PMID:
26821497
14.

Methylprednisolone-induced liver injury: Case report and literature review.

Davidov Y, Har-Noy O, Pappo O, Achiron A, Dolev M, Ben-Ari Z.

J Dig Dis. 2016 Jan;17(1):55-62. doi: 10.1111/1751-2980.12306. Review. No abstract available.

PMID:
26676833
15.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM; HCV-TARGET Study Group.

Gastroenterology. 2016 Feb;150(2):419-29. doi: 10.1053/j.gastro.2015.10.013. Epub 2015 Oct 21.

16.

Secondary sclerosing cholangitis following major burn.

Ben-Ari Z, Levingston D, Weitzman E, Haviv-Yadid Y, Cohen-Ezra O, Weiss P, Zuckerman E, Inbar Y, Amitai M, Rimon U, Goder M, Haik J.

Ann Hepatol. 2015 Sep-Oct;14(5):695-701.

17.

Ultra Low Dose Delta 9-Tetrahydrocannabinol Protects Mouse Liver from Ischemia Reperfusion Injury.

Hochhauser E, Lahat E, Sultan M, Pappo O, Waldman M, Sarne Y, Shainberg A, Gutman M, Safran M, Ben Ari Z.

Cell Physiol Biochem. 2015;36(5):1971-81. doi: 10.1159/000430165. Epub 2015 Jul 17.

18.

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research.

J Infect Dis. 2016 Jan 1;213(1):39-48. doi: 10.1093/infdis/jiv363. Epub 2015 Jul 1.

PMID:
26136470
19.

[Non-invasive assessment of liver fibrosis].

Cohen-Ezra O, Ben-Ari Z.

Harefuah. 2015 Mar;154(3):204-7, 210, 209. Review. Hebrew.

PMID:
25962254
20.

Oncogenic viruses and hepatocellular carcinoma.

Ben Ari Z, Weitzman E, Safran M.

Clin Liver Dis. 2015 May;19(2):341-60. doi: 10.1016/j.cld.2015.01.006. Epub 2015 Mar 7. Review.

PMID:
25921667

Supplemental Content

Loading ...
Support Center